Precursor Cell Lymphoblastic Leukemia-Lymphoma
Showing 9976 - 10000 of >10,000
Binge Drinking, Folate Deficiency Trial in Tulsa (Methyl Folate, Placebo)
Active, not recruiting
- Binge Drinking
- Folate Deficiency
- Methyl Folate
- Placebo
-
Tulsa, OklahomaOklahoma State University Center for Health Sciences
Apr 19, 2022
HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1
Recruiting
- HLA-A2 Positive Cells Present
- Refractory Melanoma
- Alpha-type-1 Polarized Dendritic Cells
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 12, 2022
Platelet Aggregation, Spontaneous, Coronary Artery Disease Trial in São Paulo (Colchicine 0.5 MG, Placebo)
Recruiting
- Platelet Aggregation, Spontaneous
- Coronary Artery Disease
- Colchicine 0.5 MG
- Placebo
-
São Paulo, Sao Paulo, BrazilHeart Institute (InCor) / University of São Paulo
Jul 18, 2023
Regional Nodal Basins and Gene Expression Profiling in Primary
Not yet recruiting
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Ultrasound
- 40-GEP
- (no location specified)
Jul 12, 2023
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Trial in Nanjing (6-month course of antiandrogen drugs, Long-term course of
Recruiting
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- 6-month course of antiandrogen drugs
- Long-term course of antiandrogen drugs
-
Nanjing, Jiangsu, ChinaUrology dpt, First Affiliated Hospital of Nanjing Medical Univer
Jul 13, 2023
Carcinoma,Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma Trial in Worldwide (Pemetrexed,
Active, not recruiting
- Carcinoma，Non-Small-Cell Lung
- +3 more
- Pemetrexed
- +5 more
-
Albury, New South Wales, Australia
- +192 more
Sep 19, 2022
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in United States (JCAR017, Durvalumab,
Active, not recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- JCAR017
- +7 more
-
Duarte, California
- +17 more
Jan 13, 2023
Advanced Solid Tumor, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Tumor Trial in Chicago (other, biological, drug)
Unknown status
- Advanced Solid Neoplasm
- +5 more
- Laboratory Biomarker Analysis
- +3 more
-
Chicago, IllinoisNorthwestern University
Oct 27, 2020
Colorectal Tumors Trial in New York (Botensilimab, Balstilimab)
Not yet recruiting
- Colorectal Neoplasms
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jan 24, 2023
Characterization of the Melanoma-Specific Immune Response
Recruiting
- Melanoma
-
Sacramento, CaliforniaUniversity of California, Davis Department of Dermatology
Nov 3, 2021
Either EML4-ALK Gene Rearrangements or T790M EGFR Mutation in
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
-
Hollywood, Florida
- +1 more
Sep 29, 2021
Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)
Completed
- Chronic Myeloid Leukemia
- Omacetaxine mepesuccinate
-
Los Angeles, California
- +31 more
Nov 11, 2021
Acute Myelocytic Leukemia, Myelodysplastic Syndrome Trial in Germany (Azacitidine)
Completed
- Acute Myelocytic Leukemia
- Myelodysplastic Syndrome
-
Berlin, Germany
- +10 more
Nov 12, 2021
Primary Ovarian Insufficiency Trial in Zhengzhou (Cell therapy)
Active, not recruiting
- Primary Ovarian Insufficiency
- Cell therapy
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Aug 4, 2021
Clear Cell Papillary Renal Tumor, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma Trial in Los
Recruiting
- Clear Cell Papillary Renal Neoplasm
- +10 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Oct 25, 2021
Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2, High Grade Malignant Tumor Trial in
Completed
- Blasts 10 Percent or More of Bone Marrow Nucleated Cells
- +8 more
- Cladribine
- +13 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 11, 2021
Giant Cell Arteritis Trial in France (color Doppler ultrasound and TAB in case of CDU negative)
Completed
- Giant Cell Arteritis
- color Doppler ultrasound and TAB in case of CDU negative
-
Angoulême, France
- +5 more
Apr 19, 2022
Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Anlotinib Plus Irinotecan, Irinotecan)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Anlotinib Plus Irinotecan
- Irinotecan
-
Zhengzhou, Henan, ChinaThe First Affiliated Hospital of Zhengzhou University
Aug 30, 2021
Celiac Disease Trial in Boston (Gluten Powder)
Recruiting
- Celiac Disease
- Gluten Powder
-
Boston, MassachusettsCeliac Research Centre Mass General Hospital
Jul 1, 2022
Sclerotherapy and Bone Marrow Injection In Aneurysmal Bone Cyst
Not yet recruiting
- Orthopedic Disorder
- Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst
- (no location specified)
Jan 23, 2023
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
Acute Myeloid Leukemia Trial in Suzhou (IBI188, Azacitidine)
Unknown status
- Acute Myeloid Leukemia
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Oct 19, 2020
HER2-negative Early Breast Cancer Trial in Beijing (neoadjuvant chemo upon in vitro PTC drug sensitivity screening for triple
Recruiting
- HER2-negative Early Breast Cancer
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
- neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
-
Beijing, ChinaPeking University People's Hospital
Mar 27, 2022
Obesity, Obesity, Abdominal, Insulin Resistance Trial in Kyiv, Lviv (Postbiotic, Placebo)
Recruiting
- Obesity
- +5 more
- Postbiotic
- Placebo
-
Kyiv, Ukraine
- +3 more
Mar 14, 2023
Study (EPIPHANY)
Recruiting
- Chemotherapy-induced Peripheral Neuropathy
-
Tucson, Arizona
- +11 more
Feb 28, 2022